Tuesday, November 07, 2017 12:58:01 PM
That said yes the market cap is still miniscule, one of the smallest for a fully reporting company with significant sales, about a $1.5 million mkt cap today, was $300K.
This is good, if you invest, the worst all the investors together can do if a Cat 5 runs over BWMG and kills everyone in the company is lose $1.5 million and that would not happen as insurance might pay us back for that. But what about the upside? That is why I'm in BWMG, it could be $5 million, $20 million, $40 million? There are $50 million mkt cap stocks with no sales 95% likley to go broke out there. BWMG JMHO has much higher upside than downside, super asymmetrical risk/reward.
So improved results and exposure can cause quite a rally in BWMG and management does care about share price. It only takes about another 30 or so investors to buy $10,000 or stock for it to roar JMHO.
Traditional IR is ineffective, look at GARWF and HCGS, both good value stocks that paid for outside IR and got zero or less for it.
If you show the financials and the two sticky posts at top of this to friends it will do more than traditional IR for BWMG. Look at HCGS posts here https://investorshub.advfn.com/HighCom-Global-Security-Inc-HCGS-13859/
None of those HCGS PRs gives someone a compelling reason to buy HCGS. Have told the IR firm that, not trying to be mean, and HCGS has gone no where. The two sticky posts here give someone a compelling reason to buy BWMG, because of superior value compared to other nanocaps.
Thanks for question.
Recent BWMG News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 08:27:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 07:07:39 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 04:55:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:01:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/29/2023 04:34:38 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM